United States Department of Veterans Affairs
Hepatitis C

Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin

Home > Providers' Home > Clinical Care > Guidelines > 2012 Recommendations > Supplement > Table 1

for Health Care Providers

Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin plus or minus Protease Inhibitor (Boceprevir or Telaprevir)

Update on the Management and Treatment of Hepatitis C Virus Infection

Hepatitis C Resource Center Program
National Hepatitis C Program Office

July 2012

Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin ± Protease Inhibitor (Boceprevir or Telaprevir)
Week

*Intervals may need to be increased based on patient tolerance and response to treatment in patients with significant declines in blood counts, renal insufficiency, diabetes, cirrhosis or other indications.

**Recommended for all patients at baseline and periodically during antiviral treatment in patients with diabetes, hypertension or as needed for visual complaints.

Necessary02481224Every 4-weeks ThereafterEnd-of-Treatment24 weeks Post-treatment
HCV RNA√ √√√√Follow Algorithm for additional timepoints√√
CBC with differential√√√√√√√*√
Liver function tests√√√√√√√*√
Psychiatric/Substance Use Screening√√√√√√√*
Renal panel√ √√*
Glucose√ √√*
TSH√ √√*
Uric acid (if on telaprevir)√√√√√√*√√
Pregnancy test√ √√√√√√√
Recommended
Fundoscopic Exam**√
Urine Toxicology Screen √